Puma Biotechnology Enters into Licensing Agreement with Takeda for Alisertib
By Ashish Tripathi
Pharma Deals Review: Vol 2022 Issue 10 (Table of Contents)
Published: 6 Oct-2022
DOI: 10.3833/pdr.v2022.i10.2728 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
In a bid to expand its presence in breast cancer and small cell lung cancer, Puma Biotechnology has entered into a licensing agreement with Takeda...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS